![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Celldex Stops Phase 3 Study of Brain Cancer Vaccine
Celldex Stops Phase 3 Study of Brain Cancer Vaccine
March 11, 2016
Celldex Therapeutics has pulled the plug on a Phase 3 trial of immunotherapy Rintega in patients with EGFRvIII-positive glioblastoma after a mid-trial analysis showed the candidate fared worse than a control group.
The company said last week that an independent review board concluded that the candidate would not reach its primary endpoint: statistically significant overall survival in patients with minimal residual disease.
Rintega produced a median survival rate of 20.4 months in patients, while those in the control group experienced a rate of 21.1 months, a result that “significantly outperformed expectations.”
Upcoming Events
-
21Oct